#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Heart Failure

Articles on this topic
Webinář SGLT2i v ESC HF Guidelines vs. reálná praxe

Webinar SGLT2i in ESC HF Guidelines vs. Real Practice

Dear Doctor, Boehringer Ingelheim, in collaboration with the 2nd Department of Internal…
18. 11. 2021 Source: Heart Failure
Echokardiografie_srdce_monitoring_kardiomyopatie_angina_pectoris_septum_venózní_hypertenze

Mechanisms of Cardioprotective Effects of SGLT2 Inhibitors

Inhibitors of sodium-glucose cotransporter 2 (SGLT2i, gliflozins) are a relatively new group…
18. 11. 2021 Source: Heart Failure
farmacie_antibiotika_tablety_kapsle_pilulky

Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin

Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases.…
18. 11. 2021 Source: Heart Failure
srdce srdeční selhání

Heart Failure in the Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the…
27. 10. 2021 Source: Heart Failure
žena s nadváhou si měří glukometrem inzulin

Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk

Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has…
20. 8. 2021 Source: Heart Failure
starý muž lavička park šťastný senior muž

Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease

Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It…
20. 8. 2021 Source: Heart Failure

1 2 3
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#